Urol. praxi, 2015; 16(5): 214-217

Examinations leading to prostate cancer diagnosis

MUDr.Petr Morávek jr.1, doc.MUDr.Petr Morávek, CSc. sen.2
1 Urologické oddělení, Městská nemocnice, Dvůr Králové nad Labem
2 Urologická klinika FN a LF UK v Hradci Králové

Prostate cancer is one of most serious urologic malignancies with increasing incidency in Czech Republic. Overall incidency according to

National Oncologic Registry (NOR) in the year 2000 was 60/100000 and 111/100000 in the year 2011. Prostate Cancer presents the second

most common cause of the death between the malignant disorders of the men. Initial stage of this malignancy is treatable and curable.

So early diagnose is urgent. This article gives the informations about the diagnostic methods of the prostate cancer.

Keywords: prostate cancer, diagnose

Published: December 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Morávek P, Morávek P. Examinations leading to prostate cancer diagnosis. Urol. praxi. 2015;16(5):214-217.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Smart j. Screening karcinomu prostaty. Urol List 2010; 8(1): 5-14.
    2. Potma R, Schroder FH, van Leanders, et al. Cancer detection and cancer charakteristics in the European Randomized Study of screening for Prostate Cancer (ERSPC) section Rotterdsam. Eur Urol 2007; 52: 89-97. Go to original source... Go to PubMed...
    3. Grub RL, Pinski P, Greiniee RT, et al. Prostate cancer screeniung in the Prostate, Lung,Colorectal and Ovarial cancer Trial: Update on findings from the initial four round sof screening in randomized Trial. BJU Int2008; 102(11): 1524-1530. Go to original source... Go to PubMed...
    4. Murphy AM, McKiernan JM, Olson CCA. Controvewrsies in prostate cancer screening. J Urol 2004; 172: 1822-1824. Go to original source... Go to PubMed...
    5. Mottes N (chair), et al. European Association of Urology 2014. Guidelines pro léčbu karcinomu prostaty, 1. část. Urol List 2014; 12(2): 75-76.
    6. Illic D,Neuberger MM, Djulbergeric M, etal. Screening for prostate cancer. Cochrane diabase Syst Rev 2013; 1: CD 004720. Go to original source... Go to PubMed...
    7. Mottes N (chair), et al. European Association of Urology 2014. Guidelines pro léčbu karcinomu prostat, 1. část. Urol List 2014; 12(2): 77-83.
    8. AUA University. Early detection of prostate cancer. AUA Guideline. J Urol; Guidelines Annual Meeting 2015.
    9. Wasserbauer R. Aktivní přístup k časné detekci karcinomu porostaty-Co je smysluplné a co již škodlivé. Urol List 2014; 12(2): 19-28.
    10. Belej K. Screening karcinomu prostaty. Onkologie 2009; 3(6): 351-356.
    11. Schalken JA. Diagnostika karcinomu prostaty a role PCA3. Urol List; 9(2): 18-23.
    12. Hessels D, Rittenhouseh,Schalken J, et al. Molecular Diagnostics in Prostate Cancer. EUA Update Series 2005; 6(3): 200-213. Go to original source...
    13. Van Gils MP, Cornel EB, Hessels D, et al. Molecular PCA3 diagnostic on prostate fluid. Prostate 2007; 67(8): 881-887. Go to original source... Go to PubMed...
    14. Macks LS, Pradet Y, Derus IL, et al. PCA3 molecular urine assai for prostate cancer in men undergoing repeat biopsy. Urology 2007; 69(3): 532-537. Go to original source... Go to PubMed...
    15. Fulgham PF. Transrektální biopsie prostatay naváděná ultrazvukovým vyšetřením. Urol List 2011; 9(2): 18-23.

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.